DiscGenics

07/16/2024

We are excited to announce that the U.S. FDA has allowed the Phase III clinical evaluation of our allogeneic, injectable disc progenitor cell therapy (IDCT) for painful lumbar degenerative disc disease to proceed. Subject enrollment is expected to begin in Q4 2024.

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies...

07/09/2024

We are pleased to announce publication of results in the International Journal of Spine Surgery of our combined Phase 1/Phase 2 study of IDCT, our allogeneic, injectable disc progenitor cell therapy, for lumbar degenerative disc disease.

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies...

10/19/2023

We are proud to announce a research collaboration with the U.S. Department of Veterans Affairs for tissue-engineered discs with DiscGenics' proprietary Discogenic Cells. This project, led by Sarah Gullbrand, Ph.D. at the University of Pennsylvania, has been awarded BRAVE Funding by the VA Technology Transfer Program to support a large animal study of Discogenic Cell-derived implants.

In the words of Kevin Foley, M.D., DiscGenics' Chief Medical Officer and practicing neurosurgeon: "A biologic disc replacement in lieu of existing mechanical devices would continue to change the paradigm of spine care away from a device-centric model to one of disease modification through biologic and cell-based treatments."

Learn more here:

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that...

09/26/2023

We're thrilled to announce that our CEO, Flagg Flanagan, will be presenting at the East-West BioPharma Summit from Oct 2-4 and the 2023 Cell & Gene Meeting on the Mesa from Oct 10-12. Learn more about the event in our press release!

/PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that...

09/12/2023

We recently joined Merge Medical for an insightful podcast session where we delved deep into the transformative potential of DiscGenics and our pioneering Injectable Disc Cell Therapy (IDCT). Whether you're familiar with our mission or just getting to know us, this highlight video offers a concise overview of our vision and the groundbreaking work we're doing in the realm of spinal health.

04/17/2023

With IDCT we are aiming to impact millions of lives in a big way! Need proof? Check out Dr. Gornet's brief testimonial on the extraordinary possibilities.